It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: CthulhuMythos
originally posted by: Silcone Synapse
a reply to: angelchemuel
It may be that the virus is not directly causing all of these wide ranging syptoms-but it could be making people more susceptible to stuff they already had waiting,but was triggered by the damage caused by covid.
Once your immune system takes a big hit,pretty much anything can go wrong I guess.
I agree, it is looking more like the way AIDS /HIV works where it brings down your immune system and re-activates some or all other viruses that are dormant in the body. This would explain the large variation of symptoms and severity and that people with less nutrition / poor immune systems seem to suffer more.
Researchers found that only 0.3 percent of the people they studied had contracted a confirmed case of coronavirus. Among these 236 individuals, 151 needed hospitalization, 15 needed admission into an intensive care unit (ICU) care, and 20 died.
When adjusted for factors like age and gender, this showed that people living with HIV who were taking ART meds had “the lowest risk for a COVID-19–related hospitalization.”
Overall, researchers found that people with HIV who were taking tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) were far less likely to be hospitalized or placed in the ICU when compared to other HIV-positive people taking different ART medications.
Anecdotal reports circulated about the effectiveness of the protease inhibitor darunavir against COVID-19. This prompted its manufacturer to issue a statement saying there was no laboratory evidence supporting activity of the drug against SARS-CoV-2 and that the drug showed no benefit in a small, single-arm study. Nevertheless, there are two phase III studies investigating the use of darunavir for COVID-19 (one underway and one planned).
The protease inhibitor atazanavir does have in vivo activity against SARs-CoV-2, but there are apparently no trials underway exploring its use for COVID-19.
A new nasal spray that "reduces your risk of catching Covid by 78%" has been developed by scientists.
The spray, called Taffix, costs 7p a day and claims to provide five hours of protection with a single application.
Meanwhile, the spray also contains a small amount of citric acid that slightly alters the pH within the nasal cavity, killing viruses on contact.